Recent Finacing
Recent Raise
Sorriso Pharmaceuticals develops orally deliverable, gut-stable antibody therapeutics for inflammatory bowel diseases, using a platform that produces dual TNFα/IL‑23–inhibiting antibodies with targeted intestinal activity and minimal systemic exposure.
